


MEDRAD® CT Device Portfolio



# Performance, Efficiency, and Ease of Use



Clear Direction.  From Diagnosis to Care.

**MEDRAD®** Centargo  
CT Injection System

**MEDRAD®** Stellant  
CT Injection System

# Why Choose Between Performance and Efficiency?

As a close partner to your business, our challenge is clear: decrease administrative tasks, and increase automation and efficiency without sacrificing performance, service, or reliability.

Using the same piston-based technology as our MEDRAD® Stellant injector, MEDRAD® Centargo – is the latest addition to our CT portfolio and has been carefully designed to provide exactly this.


 <p><b>Performance</b></p> <ul style="list-style-type: none"> <li>&gt; Higher maximum achievable flow rates across catheter sizes<sup>1</sup></li> <li>&gt; More consistent flow rates vs. peristaltic pumps<sup>1</sup></li> </ul>	 <p><b>Efficiency</b></p> <ul style="list-style-type: none"> <li>&gt; Daily set-up in less than two minutes</li> <li>&gt; Ready for next patient in under 20 seconds</li> </ul>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Piston-Based Performance

The type of CT injector used can impact important fluid delivery parameters. When comparing Stellant^ (a piston-based CT injector system) to a peristaltic pump-based model, Stellant^ demonstrated higher maximum achievable flow rates and more consistent steady-state flow.<sup>1</sup>

### Maximum Flow Rate


Stellant^ demonstrates higher maximum achievable flow rates with varied catheter sizes



Adapted from Figure 3 (Chaya et al., 2019). Maximum achievable flow rates (iopromide 370, 18G, 20 G and 22G catheters).  
 \*\*MEDRAD® Stellant^ significantly higher (\*\*p<0.001) than CT Exprès with all catheter sizes and CT Motion trials with catheter sizes 20 G and 22 G.  
 ^Configured with the Multi-Patient (MP) Kit.

### Flow Rate Variance

Stellant^ delivers a more consistent flow profile compared to pulsatile fluid delivery in peristaltic pump systems



Adapted from Figure 4 (Chaya et al., 2019). Flow rate variance (iopromide 370 and 20 G catheter at 4 mL/s).  
 \*\*\*p < .001


The maximum achievable flow rate dictates which protocols are compatible with a system, as some demanding protocols may require high-range flow rates.<sup>2</sup>

## Verified Delivery Rates

So, we wanted to design our newest injector, Centargo, to also deliver the same high level of performance as Stellant, as well as to streamline workflows.

The InnoVatE study helped us validate that Centargo provides higher fluid delivery with the high iodine delivery rates (IDRs) you've come to know and trust.<sup>3</sup>

### Maximum Achievable IDR With MEDRAD® Injectors



Adapted from Figure 2, Graph B (McDermott et al., 2020). Maximum achievable IDR with MEDRAD injectors through a 20 G catheter. Contrast media at room temperature.  
 \*Ordered from left to right by measured concentration/viscosity ratio


## Streamlined Workflows

The Bayer PerCent Study<sup>4</sup> was able to illustrate how Centargo also allows radiographers to maximise their time with patients, through reduced injector touch time and ease of patient changeover.

When compared to Stellant, Centargo demonstrated significantly faster patient turnover times – with time savings of 40%-63% – when using 200mL or 500 mL contrast media bottles.

These time efficiency benefits have previously only been associated with peristaltic-pump-based systems. The PerCent Study concluded that Centargo can streamline workflows while delivering the flow rate consistency and maximum achievable IDRs of Stellant.

Average Touch Time Per Patient



Adapted from Figure 7 (Kemper et al., 2022). Projected time savings depending on patient throughput, operating hours, and bottle size availability.

## Picking the Right Tool for the Job

When it comes to your practice, our portfolio of CT injector systems has something that will work for you.

Our high-performance devices are designed to fit your needs: the performance, ease of use and flexibility of Stellant, and the additional streamlined workflow offered by Centargo.

**“There is definitely a big improvement... Now, with Centargo, the changeover time and the time loss between patients has been reduced dramatically.”**

**Baljit Jagpal,**  
Lead Radiographer &  
Research Manager,  
Ninewells Hospital,  
Dundee, Scotland



#### References:

1. Chaya A, Jost G, Endrikat J. Piston-Based vs Peristaltic Pump-Based CT Injector Systems. *Radiol Technol.* 2019;90(4):344-352.
2. American College of Radiology. ACR Manual on Contrast Media. Version 10.3. [https://www.acr.org/~media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-Manual/Contrast\\_Media.pdf](https://www.acr.org/~media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-Manual/Contrast_Media.pdf). Published 2018. Accessed April 2022.
3. McDermott M, Kemper C, Barone W, Jost G, Endrikat J. Impact of CT Injector Technology and Contrast Media Viscosity on Vascular Enhancement: Evaluation in a Circulation Phantom. *Br J Radiol.* 2020;93(1109):20190868. doi:10.1259/bjr.20190868
4. Kemper CA, Muhl C, Martens B, McDermott MC, Hendriks BMF. Performance of Centargo: A Novel Piston-Based Injection System for High Throughput in CE CT. *Med Devices (Auckl).* 2022;15:79-87.

Clear Direction.  From Diagnosis to Care.

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorised Bayer representative for the most current information.

Bayer, the Bayer Cross, MEDRAD Centargo, MEDRAD, Centargo, MEDRAD Stellant, Stellant, MEDRAD Salient, and Salient are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2022 Bayer. This material may not be reproduced, displayed, modified, or distributed without the express prior written consent of Bayer.



More information on  
[radiology.bayer.com.au](http://radiology.bayer.com.au)



Centargo Manufacturer  
Imaxeon Pty Ltd  
Unit 1, 38 – 46 South Street  
Rydalmere, NSW 2116  
Australia  
Phone: 02 8845 4999  
Fax: 02 8845 4998  
Imaxeon is a Bayer subsidiary



Stellant Manufacturer  
Bayer Medical Care Inc.  
1 Bayer Drive  
Indianola, PA 15051-0780  
U.S.A.  
Phone: +1 412 767 2400  
+1 800 633 7231  
Fax: +1 412 767 4120

Australian Sponsor  
Imaxeon Pty Ltd  
Unit 1, 38 – 46 South Street  
Rydalmere, NSW 2116  
Australia  
Phone: 02 8845 4999  
Fax: 02 8845 4998  
Customer Service: 1800 633 723



Read the full  
Kemper et al (2020)  
publication on  
[www.dovepress.com](http://www.dovepress.com)